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Abstract: 
The aim of the present study was to develop evaluate mouth dissolving tablet 
of meloxicam. Drug delivery systems became sophisticated as 
pharmaceutical scientists acquire a better understanding of the 
physicochemical and biochemical parameters pertinent to their performance. 
Over the past three decades, mouth dissolving or orally disintegrating tablets 
have gained considerable attention as a preferred alternative to conventional 
tablets due to better patient compliance. The most preferrable route of drug 
administration (e.g. oral) is limited to drug candidate that show poor 
permeability across the gastric mucosa and those, which are sparingly 
soluble. A large majority of the new chemical entities and many new existing 
drug molecules are poorly soluble, thereby limiting their potential uses and 
increasing the difficulty of formulating bioavailable drug products,so lastlly 
the purpose of this study was to grow mouth dissolve tablets of Meloxicam. 
Meloxicam is a newer selective COX-1 inhibitor. These tablets were prepared 
by wet granulation procedure. The tablets were evaluated for % friability, 
wetting time and disintegration time. Sublimation of camphor from tablets 
resulted in better tablets as compared to the tablets prepared from granules 
that were exposing to vacuum. The systematic formulation approach helped 
in understanding the effect of formulation processing variables. 
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Introduction  
Orally administered dosages form e.g. tablets, capsules 
are convenient dosage form for many drugs –but they 
are challenging to the formulate if the active substances 
has poor dissolution or low bioavailability. Polymer 
coating enables the formulation of mouth dissolving 
and taste masking of bitter taste drugs-thereby giving 
better  patient  compliance  [1].  Tablets   that   are  fast 
 
 
 disintegrate or dissolve rapidly in the patient’s mouth, 
are convenient for young children, aged and patients 
with swallowing difficulties [2]. For these 
formulations, the small volume of saliva is usually 
sufficient to result in tablet disintegration in the oral 
cavity [3]. The medication then be absorbed partially or 
entirely   into   the  systemic  circulation   from   blood 
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vessels in the sublingual mucosa, or it can be 
swallowed as a solution to be absorbed from the 
gastrointestinal tract (GIT) [4].  
The bioavailability of some drugs may be enhance due 
to absorption of drugs in oral cavity and also due to 
pregastric absorption of saliva containing dispersed 
drugs that pass down into the stomach. The amount of 
drug that is subject to first pass metabolism is reduced 
as compared to mouth dissolving  tablets [5]. Orally 
disintegrating tablets contain  wide variety of 
pharmaceutical active ingredients covering many 
therapeutic categories. The time for disintegration of 
orally disintegrating tablets are generally considered 
less than one minute. Orally disintegrating tablets are 
characterized by high porosity, low density and low 
hardness. When administered, an in-situ suspension is 
created in the oral cavity as the tablet disintegrates and 
is subsequently swallowed [6]. Recently, the 
Nomenclature and Labeling committee at USP has 
approved the Orally Disintegrating Tablets 
terminology. 
Meloxicam is a nonsteroidal anti-inflammatory drug of 
the oxicam class, used to relieve the symptoms of 
arthritis, primary dysmenorrhea, fever and as an 
analgesic, especially where there is an inflammatory 
component [7]. Meloxicam inhibits cyclooxygenase 
(COX) synthesis. This enzyme is responsible for 
converting arachidonic acid into prostaglandin H2. This 
is the first step in the synthesis of prostaglandins, 
which are mediators of inflammation. Meloxicam has 
been shown, especially at its low therapeutic dose, 
selectively to inhibit COX-2 over COX-1 [8]. 
A primary advantage of the oxicam family of drugs is 
their long half-life which permits once-day dosing [9]. 
In gastric disease, lower dose of meloxicam is required 
7.5 mg/day. Meloxicam is safer then other NSAID’s 
[10]. The fundamental approach used in the progress of 
the fast-dissolving or mouth dissolving tablet is the use 
of a super disintegrants. Sodium starch glycolate, and 
crospovidone were screened in the present study. A 
different approach used in developing Mouth 
dissolving tablets is maximizing the pore arrangement 
of the tablets [11]. I Freeze-drying and II vacuum-
drying techniques have been tried by researchers to 
maximize the pore structure of tablet matrix. Freeze 
drying is burdensome and it yields brittle and 
hygroscopic products. Consequently, it was determined 
to accept the vacuum-drying technique in the present 
study [12-14]. Vacuum drying was adopted after 
adding of a subliming agent to augment porosity of the 
tablets. It is possible that a porous hydrophilic matrix 
will easily pick up the disintegrating medium and break 
quickly. NSAIDs are the most recurrently prescribed 
by physicians for inflammatory disorders. NSAIDs 
exert their effect through inhibition of cyclooxygenase-
II, the main form of isozyme associated with 
inflammation but the simultaneous inhibition of 
cyclooxygenase-I and the resulting gastric and renal 
dysfunction limit their frequent use [15-17]. 
 
Materials 
Meloxicam was gifted from Zydus Hetero drugs Ltd. 
(Hyderabad, India). Crospovidone was gifted from Red 
son Pharmaceuticals (Ahmedabad, India). Sodium 
starch glycolate and lactose-IP were was gifted samples 
from Mundipharama Pvt. Ltd. (Delhi, India). 
Polyvinylpyrrolidone (PVP-K40) and colloidal silicon 
dioxide were obtained from Gaurav pharma 
(Ahmedabad, India), Magnesium stearate was gifted 
from Kotharipharma Pvt. Ltd. (Sagar, India). 
 
Method Preparation of granules 
All ingredients were weighted as per required quantity 
and store separately. To maintain uniformity the 
particle size, each material was passed through # 100 
mesh-sized screen before mixing.  
 
Table 1. List of ingredients used in formulation of 
fast dissolving tablets of Meloxicam 
 
Batch No. Ingredients  
 AI AII AIII AIV AV 
Meloxicam. (mg) 7.5 7.5 7.5 7.5 7.5 
Crospovidone. (mg) 10 10 10 10 10 
Colloidal Silica 
dioxide. (mg) 
- 1 2 1 2 
Camphor. (mg) 10 10 20 20 - 
Lactose .(mg) 150 150 150 150 150 
Talc 1% 1% 1% 1% 1% 
Magnesium Stearete 0.8
% 
0.8% 0.8
% 
0.8% 0.8
% 
PVP solution  in 
ethyl alcohol 
 
10% 10% 10% 10% 10% 
 
Camphor, crospovidone, and lactose were mixed using 
a glass pestle & mortar, and then added Meloxicam. 
Prepare a alcoholic solution of Polyvinylpyrrolidone 
(PVP) 15% w/v, it was added in the mixture in such 
quantity that sufficient to bind the mass. Then that 
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mass was passed through 100 mesh sized screen and 
granules was collected. Theses granules were dried 
(Vacuume dried) at about 60°C for 24 hrs that facilitate 
sublimation of camphor. Prepared granules were mixed 
with the crospovidone. These granules were lubricated 
with 1% w/w of talc and 0.8 % w/w of magnesium 
stearate. 
Tablets formation by single punch machine 
Dried granules were compressed by using single-punch 
tablet machine (Cadmach, Bhopal India) and converted 
into tablets. Sublimation was performed from tablets 
instead of granules at 60°C in selected batches. 
 
Table 2. Various evaluation parameters of prepared tablets batches of Meloxicam 
 
Batch 
No.  
Hardness 
(kg/cm2)  
Friability 
(%)  
Weight  
variation  
Thickness  
(mm) ±S.D  
Waiting 
Time (sec) 
Disintegration  
Time (sec)  
AI  3.56 ± 0.01  0.19  Passes  2.91± 0.2  101.21  1 min. 12 sec.  
AII  4.25± 0.01  0.23  Passes  2.69± 0.1  100.07  1 min.10 sec.  
AIII  3.04± 0.02  0.21  Passes  2.66± 0.1  99.90  59 sec.  
AIV  3.14± 0.04  0.26  Passes  2.48± 0.1  98.12  52 sec.  
AV  3.99± 0.03  0.22  Passes  2.74± 0.1  100.95  1 min 02 sec.  
 
Evaluation of tablet properties 
I. Hardness 
The crushing strength or hardness of the tablets was 
measured with help of a Monsanto hardness tester and 
expressed in kg/cm2. 
 
II. Uniformity of Weight 
Weight variation test is done with 20 tablets. It is the 
individual variation of tablet weight from the average 
weight of 20 tablets. 
 
III. Friability 
The friability of tablets using 10 tablets as a sample 
was measured using a Roche Friabilator. Tablets were 
rotated at 25 rpm for 4 minutes or up to 100 
revolutions. The tablets were then reweighed after 
removal of fines and the percentage of weight loss was 
calculated.  
 
IV. Disintegration Time 
Disintegration time for MDTs was determined using 
USP disintegration apparatus with SSF (pH 6.2, 900 ml 
at 37°C) as the disintegrating medium. To comply the 
test all tablets should disintegrate within 3 minutes.  
 
V. Dissolution Time 
Dissolution Study of Tablets On the basis of 
disintegration data, formulation I, II and III was chosen 
for dissolution study, as it was showing least 
disintegration time i.e. 52 seconds. In vitro dissolution 
study on prepared tablets was performed in SSF (pH 
6.2) using USP type II (paddle) apparatus operated at 
50 rpm (900 ml) for 60 minutes (37 ± 0.5°C). 
 
VI. Wetting Time 
The wetting time of the tablets was measured using a 
very simple process. Five circular tissue papers of 10-
cm diameter were placed in a Petri dish with a 10-cm 
diameter. Ten milliliters of water containing a water-
soluble dye (eosin) was added to the Petri dish. A tablet 
was carefully placed on the surface of tissue paper. The 
time required for water to reach the upper surface of 
the tablet was noted as the wetting time. All tests are 
summarized in Table 2. 
                  
 
  Figure 1. Dissolution profile of batch AI, AII, AIII 
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Results and Discussion 
Water insoluble diluents such as microcrystalline 
cellulose and dicalcium phosphate were not used in this 
study because they can be expected to cause an 
unacceptable feeling of grittiness in the patient mouth. 
Along with the soluble diluents, lactose was selected as 
a soluble diluents considering its advantages in terms 
of availability, low cost and relative moisture 
insensitivity. Polyvinylpyrrolidone was used as a 
binder at a concentration of 15% wt/vol, in ethyl 
alcohol considering its well-known applicability in the 
pharma industry. The crushing strength of the tablets 
was adjusted 3.14 to 4.25 kg/cm2.Sublimation agents 
such as menthol, camphor and thymol were used to 
increase porosity of the tablets. Camphor-containing 
tablets show faster disintegration or shorter 
disintegration time as compared with tablets containing 
menthol and thymol. The batches AI, AIII and AV 
were prepared using camphor at different 
concentrations to study its effect on disintegration time. 
The sublimation time (5-10 hrs) depending upon the 
quantity of camphor present initially (10%, 20% and 
0%). 
The results shown in Table 1 indicate that 
concentration-dependent disintegration was observed in 
batches prepared using camphor as a sublimation agent. 
The porous structure is responsible for faster water 
uptake, hence it facilitates wicking action of 
crospovidone in bringing about faster disintegration. In 
the first few attempts (AI, AIII and AV), sublimation 
of camphor was performed from granules prior to 
compression into tablets. Batches AI, AII and AV 
showed good mechanical integrity, but the 
disintegration time was a little longer than the 
arbitrarily chosen value of less than 60 seconds. In 
Batch AIV, sublimation was performed after 
compression. The results showed in Table 1 reveal that 
sublimation of camphor from tablets resulted in faster 
disintegration. The compaction process might have 
caused breakage of porous granules and subsequent 
reduction in porosity. The low value of wetting time 
and disintegration time indicate that the porosity of 
tablets of batch AIV would be greater than batches AI, 
AII and  AV. The granules required 2 hours of vacuum 
drying, whereas the tablets required 10 hours of 
vacuum drying. The longer drying time was required in 
the case of tablets probably because of the decreased 
surface area and porosity. In order to investigate the  
 
factors systematically, a factorial design was employed 
in the present investigation. 
On the basis of above results it can be concluded that 
an oral disintegrating tablet of Lornoxicam can be 
prepared.  
 
Conclusion 
In this research work it was found that the amount of 
camphor and crospovidone considerably affect 
thevarrious parameters such as waiting rime, 
disintegration time, and percentage friability. It is thus 
concluded that by adopting a systematic formulation 
approach, an optimum point can be reached in the 
shortest time with minimum efforts. Vacuum-drying 
technique would be an effective alternative approach 
compared with the use of more expensive adjuvant in 
the formulation of Mouth Dissolving tablets. 
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